Abstract
Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9), as a versatile genome engineering tool, has become popular in the biology research field and it was also applied to optimize tumor immunotherapy. Moreover, CRISPR-based high-throughput screening can be used in the study of immunomodulatory drug resistance mechanism. In this review, we summarized the development as well as the application of CRISPR/Cas9 technology in the cancer immunotherapy and discussed the potential problems that may be caused by this combination.
Highlights
Given that the incidence of cancer is gradually increasing even with the improved prognosis techniques [1], methods for cancer therapy are widely investigated and the chemotherapy, radiotherapy and surgery are commonly used to prolong survival time of cancer patients
There are many issues that should be considered in the application of Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system in immunotherapy, such as off-target effect, editing efficiency and clinical safety which provide challenges to researchers
Studies indicated that the offtarget mutagenesis mediated by CRISPR/Cas9 may be different due to different single guide RNA (sgRNA) design and target sequences [101]
Summary
Given that the incidence of cancer is gradually increasing even with the improved prognosis techniques [1], methods for cancer therapy are widely investigated and the chemotherapy, radiotherapy and surgery are commonly used to prolong survival time of cancer patients. Chimeric antigen receptor T therapy, immune checkpoints blockade and genetically engineered macrophages have provided multi-mode methods to target and destroy cancer cells. Using CRISPR/Cas9 technology to knock out immune checkpoints such as programmed death-1 (PD-1), programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) may provide a new direction for cancer immunotherapy [15].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.